{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.402","upperLimit":"6.867","value":"5.092"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG000","title":"Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.","reportingStatus":"POSTED","timeFrame":"From Month 37 to Month 84 (up to approximately 47 months)","title":"Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator","type":"SECONDARY","unitOfMeasure":"months"}